Asset profile
ENERGI-F705
Small molecule
Evidence outlook
Mid-stage studies underway, no completed readout
Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
60 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 39 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| ENERGI-F705: this drug | Phase 2 | Small molecule | alpha-synuclein / mitochondrial ATP | ||
| Amantadine ER (Gocovri / ADS-5102) | Approved | Small molecule | NMDA receptor | ||
| Apomorphine (Apokyn) | Approved | Small molecule | dopamine | ||
| Apomorphine Sublingual Film (Kynmobi) | Approved | Small molecule | dopamine | ||
| Crexont (IPX203) | Approved | Small molecule | dopamine precursor | ||
| Entacapone (Comtess) | Approved | Small molecule | COMT | ||
| Foslevodopa / Foscarbidopa (Vyalev) | Approved | Small molecule | dopamine precursor | ||
| Inbrija (CVT-301) | Approved | Small molecule | dopamine precursor | ||
| Istradefylline (Nourianz) | Approved | Small molecule | adenosine A2A | ||
| Levodopa-Carbidopa Intestinal Gel (Duopa) | Approved | Small molecule | dopamine precursor | ||
| Opicapone (Ongentys) | Approved | Small molecule | COMT, PDE4 | ||
| Parcopa | Approved | Small molecule | dopamine precursor | ||
| Pimavanserin (Nuplazid) | Approved | Small molecule | 5-HT2A/2C receptor, Serotonin 5-HT2A receptor (antagonist / inverse agonist) | ||
| Pramipexole (Sifrol/Mirapex) | Approved | Small molecule | Dopamine D2/D3 receptors | ||
| Pramipexole ER (Mirapex ER) | Approved | Small molecule | Dopamine D2 / D3 receptors | ||
| Rasagiline (Azilect) | Approved | Small molecule | MAO-B |
…and 45 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2030 (1)
January 2030 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.